Peter Hillmen

19PUBLICATIONS
56CO-AUTHORS
HaematologyCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jan 22, 2024
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline.

Austin Kulasekararaj, Jamie Cavenagh, Inderjeet Dokal

|Nov 17, 2022
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.

Peter Hillmen, Barbara Eichhorst, Jennifer R Brown

|Aug 26, 2022
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.

Talha Munir, Jake Emmerson, Anna Hockaday

|Jul 18, 2022
Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK.

Peter Hillmen, Jing Xie, Alan S M Yong

|Aug 12, 2021
Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells.

Adam J Linley, Laura I Karydis, Anil K Mondru

|Jul 26, 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.

John C Byrd, Peter Hillmen, Paolo Ghia

Pageof 4

Frequent Collaborators

2 joint publications

Martin J S Dyer

2 joint publications

Deborah M Stephens

2 joint publications

Paolo Ghia

2 joint publications

John C Riches